Clinical Trials on Risk Assesment in Russian Federation

Total 26 results

Moscow Regional Research and Clinical Institute...

Completed

Effect of Perioperative Dexmedetomidine Administration on Outcome in Cardiac Surgery Patients

Patient Outcome Assessment

Russian Federation
Tver Regional Perinatal Center

Completed

Effect of Intra-abdominal Pressure to the Level of the Sensory Block at Caesarean Section Under Spinal Anesthesia (IAPSB)

Obstetric Anesthesia Problems | High-Risk Pregnancy

Russian Federation
University of Illinois at Chicago
National Institute on Drug Abuse (NIDA); Prisma Research Center

Completed

Tajik Migrant Health Education Study

HIV Infections | Hepatitis C | Risk Reduction Behavior | Risky Health Behavior

Russian Federation
Atlas Biomed

Withdrawn

Dietary Fibers Effect on the Gut Microbiota Composition

Inflammation | Metabolic Syndrome | Dyslipidemias | Cardiovascular Risk Factor | Microbiome

Russian Federation
Center of Personalized Medicine, Pirogova
University of Rochester; I.M. Sechenov First Moscow State Medical University; Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health and other collaborators

Completed

Personalized Evidence-based Medicine in Patients With Atrial Fibrillation

Adherence to Personalized EBM Anticoagulant Treatment in Patients at High Risk for Stroke

Russian Federation
Meshalkin Research Institute of Pathology of Circulation

Unknown

Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism (PSCAT)

Pulmonary Embolism | Intermediate-high Risk | Combination of Oral Anticoagulation Therapy and Sildenafil

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in Relapse

Russian Federation
Tomsk National Research Medical Center of the Russian...

Recruiting

Telecommunication Technology-based Online Survey

COVID-19 | Risk Factors | Polypharmacy | Drug Interactions | Self Medication

Russian Federation
Moscow Clinical Scientific Center

Recruiting

A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations (Def_Special)

Breast Cancer | Solid Tumor | Gastrointestinal Cancer | Gynecological Malignancies | High-Risk Cancer | Myelosuppression

Russian Federation
Federal State Budgetary Institution, V. A. Almazov...

Completed

Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease

Increased Risk of SARS-CoV-2 Infection

Russian Federation
Eurasian Association of Therapists

Completed

Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection (ACTIV-2)

Diabetes | Covid19 | Death | Atrial Fibrillation | Risk Factor, Cardiovascular | CKD | COPD | Comorbidities and Coexisting Conditions | DVT

Russian Federation
Federal State Budgetary Institution National Medical...
Kemerovo Cardiology Center, Tarasov Roman Sergeevich; Tomsk National Research...

Recruiting

Management Tactics for Patients High Risk With Acute Coronary Syndrome Without ST Segment Elevation and Multivessel Coronary Artery Disease (NSTE-ACSMT)

Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients

Russian Federation
AstraZeneca

Completed

Non-Interventional Study PREVENT (PREVENT)

Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients

Russian Federation
Medtronic BRC

Completed

Reveal® XT Performance Trial (XPECT)

Atrial Fibrillation | Risk of Cardiac Arrhythmias

Netherlands, Germany, Austria, Belgium, Canada, Czech Republic, Russian Federation, Slovakia
Octapharma

Completed

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Significant Bleeding Risk

Russian Federation, United States, Romania, Ukraine, Belarus, Bulgaria, Georgia, Germany, Moldova, Republic of, Poland, Spain
Sanofi
Bristol-Myers Squibb

Terminated

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Russian Federation, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Denmark, Finland, H... and more
Boston Scientific Corporation

Completed

Registry on WATCHMAN Outcomes in Real-Life Utilization (EWOLUTION)

Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke

Ireland, Spain, Germany, Netherlands, France, United Kingdom, Italy, Russian Federation, Portugal, Belgium, Poland, Saudi Arabia, United Arab Emirates
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Population Health Research Institute
Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation...

Recruiting

Prospective Urban Rural Epidemiology Study (PURE)

Cardiovascular Diseases | Lung Diseases | Cancer | Risk Factor, Cardiovascular | Health Behavior | Injuries | Environmental Exposure | Renal Disease | Communicable Disease

India, Saudi Arabia, Iran, Islamic Republic of, Peru, Pakistan, Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, Kazakhstan, Kyrgyzstan, Malaysia, Palestinian Territory, occupied, Philippines, Poland, Russian Federation and more
Bristol-Myers Squibb

Completed

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

High Risk Stage III Melanoma

Italy, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
Advaxis, Inc.
Gynecologic Oncology Group

Terminated

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer (AIM2CERV)

High Risk Cervical Cancer | Advanced Cervical Cancer

United States, Argentina, Brazil, Canada, Chile, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Serbia, Spain, Taiwan, Ukraine
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
AstraZeneca
The Cleveland Clinic; IQVIA RDS Inc.

Completed

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
AstraZeneca

Completed

European Study of Cardiovascular Risk (EURIKA)

Smoking | Hypertension | Obesity | Diabetes | Hyperlipidemia | Cardiovascular Risk Factors

Sweden, France, Russian Federation, Spain, Turkey, United Kingdom, Germany, Norway, Austria, Belgium, Switzerland, Greece
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Novo Nordisk A/S

Recruiting

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)

Inflammation | Chronic Kidney Disease | Cardiovascular Risk

Korea, Republic of, Spain, China, Taiwan, Mexico, Netherlands, Latvia, Malaysia, United States, Thailand, Italy, Hungary, Australia, Poland, South Africa, India, Portugal, Romania, United Kingdom, Brazil, Sweden, Lithuania, Japan, Serbia and more

Clinical Trials on Risk Assesment in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations